Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Kesimpta Market Growth Potential: How Will Market Size Change Through 2030?
Growth during the historical phase resulted from several key influences: the shortcomings of conventional multiple sclerosis treatments, a rise in the frequency of MS diagnoses, progress in monoclonal antibody research, acceptance by neurologists of B-cell targeting strategies, and a need for straightforward dosing options.
The upward trajectory during the forecast period is driven by a larger pool of relapsing MS patients, a higher uptake of home injections, broader use in progressive MS subtypes, better treatment compliance, and increased funding for neurological healthcare. Key developments shaping this period involve a move toward B cell-depleting therapies, a growing preference for self-administered MS medications, more emphasis on early-stage MS management, greater adoption of targeted immunotherapies, and the expansion of neurology services delivered at home.
Download A Free Sample Report For Comprehensive Market Insights:
Kesimpta Market Expansion Supported By Key Demand Factors
The growing incidence of multiple sclerosis (MS) is anticipated to boost the kesimpta market in the coming years. MS is a chronic autoimmune disorder impacting the central nervous system, which results in nerve fiber deterioration and manifests as muscle weakness, visual disturbances, and cognitive decline. This upward trend in MS prevalence is linked to enhanced diagnostic capabilities, greater disease awareness, and more efficient reporting mechanisms. Kesimpta is designed for relapsing forms of MS by targeting B-cells to diminish flare-ups and decelerate disability progression. For example, in August 2025, Neurologia i Neurochirurgia Polska, a peer-reviewed medical journal in Poland, reported that MS incidence in China is on the rise, with annual estimates ranging from 0.2 to 0.6 per 100,000 individuals. In Turkey, the 2022 MS incidence rate was 6.2 per 100,000 people, while Saudi Arabia sees increasing rates, with recent estimates between 3 and 5 per 100,000 annually. Consequently, the escalating prevalence of MS is fueling expansion in the kesimpta market.
Kesimpta Market Driver: Impact Of Rising Healthcare Expenditure On The Market Growth
A surge in healthcare spending is predicted to drive further growth in the kesimpta market. Healthcare expenditure encompasses all costs related to medical services, such as hospital care, research, pharmaceuticals, public health initiatives, and associated activities. This increase is fueled by an aging population, a higher burden of chronic illnesses, technological progress in medicine, and escalating treatment expenses. Investments in healthcare for Kesimpta aim to enhance patient outcomes by lowering relapse rates and slowing disease progression. In May 2024, the Office for National Statistics, a UK government body, reported that total healthcare spending rose by 5.6% in nominal terms from 2022 to 2023, compared to a 0.9% increase in 2022. Moreover, long-term health and social care expenditures grew by 2.8% in real terms in 2022. Thus, rising healthcare expenditure is a key factor propelling the kesimpta market forward.
Kesimpta Market Segments: Where Are The Largest Growth Opportunities?
The kesimpta market covered in this report is segmented –
1) By Indication: Treatment Of Rhabdomyosarcoma (RMS), Treatment Of Clinically Isolated Syndrome (CIS), Treatment Of Active Secondary Progressive Multiple Sclerosis (SPMS)
2) By Formulation: Injectable formulation, Pre-filled Syringes Or Autoinjectors
3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Specialty Pharmacies, Home Healthcare Providers, Neurology Clinics
Kesimpta Market Growth Trends Influencing Competitive Dynamics
A central development in the Kesimpta market involves a self-administered, targeted B-cell therapy designed to address relapsing forms of multiple sclerosis (RMS). This treatment modality offers both efficacy and convenience, effectively reducing relapses and decelerating disease progression. For example, in April 2024, Novartis AG, a pharmaceutical firm headquartered in Switzerland, unveiled six-year efficacy data for its RMS medication, Kesimpta (ofatumumab). The findings emphasize considerable advantages for patients recently diagnosed with relapsing multiple sclerosis who had not previously received treatment. This evidence originates from the ALITHIOS open-label extension study, highlighting the critical role of early therapeutic intervention in managing this persistent disease.
Kesimpta Market Major Participants And Competitive Dynamics
Major companies operating in the kesimpta market are Novartis AG
Access The Complete Kesimpta Market Report:
Kesimpta Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the kesimpta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kesimpta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model